0001493152-23-002974.txt : 20230130 0001493152-23-002974.hdr.sgml : 20230130 20230130170104 ACCESSION NUMBER: 0001493152-23-002974 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230126 FILED AS OF DATE: 20230130 DATE AS OF CHANGE: 20230130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McNulty Christopher CENTRAL INDEX KEY: 0001701459 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37769 FILM NUMBER: 23568704 MAIL ADDRESS: STREET 1: C/O INVIVO THERAPEUTICS HOLDINGS CORP. STREET 2: 1 KENDALL SQUARE, SUITE B14402 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VBI Vaccines Inc/BC CENTRAL INDEX KEY: 0000764195 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 160 SECOND STREET STREET 2: CAMBRIDGE CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-830-3031 MAIL ADDRESS: STREET 1: 160 SECOND STREET STREET 2: CAMBRIDGE CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: SciVac Therapeutics Inc. DATE OF NAME CHANGE: 20150717 FORMER COMPANY: FORMER CONFORMED NAME: LEVON RESOURCES LTD. DATE OF NAME CHANGE: 20100910 FORMER COMPANY: FORMER CONFORMED NAME: LEVON RESOURCES LTD DATE OF NAME CHANGE: 19850305 4 1 ownership.xml X0306 4 2023-01-26 0 0000764195 VBI Vaccines Inc/BC VBIV 0001701459 McNulty Christopher C/O VBI VACCINES INC., 160 SECOND STREET, FLOOR 3 CAMBRIDGE MA 02142 1 1 0 0 CFO and Head of BD Option (Right to Buy Common Shares) 0.575 2023-01-26 4 A 0 75000 0 A 2033-01-26 Common Shares 75000 75000 D The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 26, 2023 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 26, 2023 (the "Option Agreement"). 25% of the options vest and become exercisable on the one-year anniversary of the Grant Date, with the remaining 75% of the options vesting and becoming exercisable in 24 equal monthly installments beginning on the first day of the month following the one-year anniversary of the Grant Date, subject to the reporting person's employment on the relevant vesting date. The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. /s/ Christopher McNulty 2023-01-30